Figure 1.





Figure 2.


RANDOMIZATION (Day 1)
Day -28 to -6
Day -5 to -1
Week 4 (Day 29)
Week 8 (Day 57)
Week 12 (Day 85)
Week 48 (Day 337)
Week 52 (Day 365)
Screening visit
Baseline visit
Treatment Arm A (60 patients)
Treatment Arm B (60 patients)
Treatment Arm C (60 patients)
Treatment Arm D (60 patients)
Treatment epoch
BYM338 10 mg/kg intravenous infusion every 4 weeks for 48 weeks
Treatment epoch
BYM338 3 mg/kg intravenous infusion every 4 weeks for 48 weeks
Treatment epoch
BYM338 1 mg/kg intravenous infusion every 4 weeks for 48 weeks
Treatment epoch
Placebo intravenous infusion every 4 weeks for 48 weeks
VARIABLE DURATION (0 up to 52 weeks MAXIMUM)
Maintenance Treatment epoch - see Figure 3-2
BYM338 10 mg/kg i.v. infusion every 4 weeks
VARIABLE DURATION (0 up to 52 weeks MAXIMUM)
Maintenance Treatment epoch - see Figure 3-2
BYM338 3 mg/kg i.v. infusion every 4 weeks
VARIABLE DURATION (0 up to 52 weeks MAXIMUM)
Maintenance Treatment epoch - see Figure 3-2
BYM338 1 mg/kg i.v. infusion every 4 weeks
VARIABLE DURATION (0 up to 52 weeks MAXIMUM)
Maintenance Treatment epoch - see Figure 3-2
Placebo i.v. infusion every 4 weeks
Post-treatment Follow Up epoch (28 days)
Post-treatment Follow Up epoch (28 days)
Post-treatment Follow Up epoch (28 days)
Post-treatment Follow Up epoch (28 days)
Legend
= up to 22 days
= up to 5 days
= 52 weeks
= VARIABLE DURATION (0 to 52 weeks)
= 28 days
* Once last patient last treatment occurs, subjects will return to site ~28 days after their last study drug administration for an end of treatment epoch visit, then enter post-treatment follow up for 28 days.